NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Biomarkers of Cervical Spondylotic Myelopathy
Biomarkers of Cervical Spondylotic Myelopathy

NCT07772297

Not Yet RecruitingN/A

Sponsor: University of California, San Francisco

Conditions: Cervical Spondylotic Myelopathy

Countries: United States

Investigators believe that patients with cervical spondylotic myelopathy (CSM) have measurable changes in certain molecules in their blood compared with people without CSM. Investigators expect that these changes may be related to how severe a patient's condition is based on imaging and clinical exams. Investigators will also study how these molecules change before and after surgery to see whether they are related to how well patients recover. By combining these blood markers with clinical and imaging information, investigators hope to develop a tool that may help predict patient outcomes.

Eligibility overview

Sex: ALL

Age: 18 Years to

Healthy volunteers: Yes

Study type: OBSERVATIONAL

Eligibility criteria
Healthy Inclusion Criteria:

* Age \>18
* No neck pain
* No radiculopathy or myelopathy symptoms
* No trauma in the past 6 months
* Does not meet exclusion criteria.

CSM Inclusion Criteria:

* Age \>18
* Diagnosis of/encompassed by/related to cervical spondylotic myelopathy, cervical myelopathy, ossification of posterior longitudinal ligament.

Healthy Exclusion Criteria:

* Age \<18.
* Malignancy
* Trauma in the past 6 months
* Infectious etiology
* Prior cervical spine surgery.
* Symptoms of cervical radiculopathy, myelopathy or neck pain.

CSM Exclusion Criteria:

* Age \<18.
* Malignancy
* Trauma in the past 6 months
* Infectious etiology.
* Prior cervical spine surgery.
* MRI or CT imaging demonstrating an alternative cause for cervical myelopathy that is not degenerative stenosis (i.e. transverse myelitis, tumor compressing cord, pathologic fracture).
Locations (1)
  • San Francisco, California, United States